We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vifor

News List

US clears Cara, Vifor's Korsuva to treat itching in CKD patients firstwordpharma
August 24, 2021
Cara Therapeutics and Vifor Pharma said Monday that the FDA has approved Korsuva (difelikefalin) to treat moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing haemodialysis.
Treatment for hyperkalaemia recommended by NICE for NHS europeanpharmaceuticalreview
December 19, 2019
NICE has recommended patients in England have access to a new treatment option for treating hyperkalaemia (raised serum potassium levels) in adults.
Vifor Fresenius snap up rights to Cara’s itch therapy pharmafile
May 25, 2018
The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and an equity investment of $20 million to gain the Ex-US, Japan and South Korea rights to Cara Therapeutics’ Korsuva.
Vifor’s hyperkalaemia drug Veltassa approved in Europe pharmaphorum
July 24, 2017
Vifor Pharma has gained final European marketing approval for its hyperkalaemia treatment Veltassa.